Skip to main content

Advertisement

SpringerLink
Log in

Doxorubicin and irinotecan drug-eluting beads for treatment of glioma: a pilot study in a rat model

  • Published:
Journal of Materials Science: Materials in Medicine Aims and scope Submit manuscript

Abstract

Despite some progress in therapy, the prognosis of patients with malignant gliomas remains poor. Local delivery of cytostatics to the tumour has been proven to be an efficacious therapeutic approach but which nevertheless needs further improvements. Drug Eluting Beads (DEB), have been developed as drug delivery embolisation systems for use in trans-arterial chemoembolisation. We tested in a rat model of malignant glioma, whether DEB, loaded with doxorubicin or irinotecan, may be used for local treatment of brain tumours. Unloaded and drug loaded DEB were implanted into the brains of healthy and tumour bearing BD IX rats followed by histological investigations and survival assessment. Intracerebral implantation of unloaded DEB caused no significant local tissue damage, whilst both doxorubicin and irinotecan DEB improved survival time significantly. However, a significant local toxicity was found after the implantation of doxorubicin DEB but not with irinotecan DEB. We concluded that irinotecan appears to be superior in terms of the risk-benefit ratio and that DEB may be used for local treatment of brain tumours.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Chakravarti A, Palanichamy K. Overcoming therapeutic resistance in malignant gliomas: current practices and future directions. Cancer Treat Res. 2008;139:173–89.

    CAS  PubMed  Google Scholar 

  2. Mason WP. Emerging drugs for malignant glioma. Expert Opin Emerg Drugs. 2008;13(1):81–94.

    Article  CAS  PubMed  ADS  Google Scholar 

  3. Sawyer AJ, Piepmeier JM, Saltzman WM. New methods for direct delivery of chemotherapy for treating brain tumors. Yale J Biol Med. 2006;79(3–4):141–52.

    CAS  PubMed  Google Scholar 

  4. Guerin C, Olivi A, Weingart JD, Lawson HC, Brem H. Recent advances in brain tumor therapy: local intracerebral drug delivery by polymers. Invest New Drugs. 2004;22(1):27–37.

    Article  CAS  PubMed  Google Scholar 

  5. Lawson HC, Sampath P, Bohan E, Park MC, Hussain N, Olivi A, et al. Interstitial chemotherapy for malignant gliomas: the Johns Hopkins experience. J Neurooncol. 2007;83(1):61–70.

    Article  CAS  PubMed  Google Scholar 

  6. Lesniak MS, Upadhyay U, Goodwin R, Tyler B, Brem H. Local delivery of doxorubicin for the treatment of malignant brain tumors in rats. Anticancer Res. 2005;25(6B):3825–31.

    CAS  PubMed  Google Scholar 

  7. Noble CO, Krauze MT, Drummond DC, Yamashita Y, Saito R, Berger MS, et al. Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: pharmacology and efficacy. Cancer Res. 2006;66(5):2801–6.

    Article  CAS  PubMed  Google Scholar 

  8. Lin SH, Kleinberg LR. Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies. Expert Rev Anticancer Ther. 2008;8(3):343–59.

    Article  CAS  PubMed  Google Scholar 

  9. Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol. 2003;5(2):79–88.

    Article  CAS  PubMed  Google Scholar 

  10. Westphal M, Ram Z, Riddle V, Hilt D, Bortey E. Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial. Acta Neurochir (Wien). 2006;148(3):269–75. discussion 275.

    Article  CAS  Google Scholar 

  11. Garside R, Pitt M, Anderson R, Rogers G, Dyer M, Mealing S, Somerville M, Price A, Stein K. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation. Health Technol Assess. 2007;11(45):iii–iv, ix–221.

  12. Omuro AM, Delattre JY. Editorial: what is new in the treatment of gliomas? Curr Opin Neurol. 2007;20(6):704–7.

    Article  PubMed  Google Scholar 

  13. von Eckardstein KL, Reszka R, Kiwit JC. Intracavitary chemotherapy (paclitaxel/carboplatin liquid crystalline cubic phases) for recurrent glioblastoma–clinical observations. J Neurooncol. 2005;74(3):305–9.

    Article  CAS  Google Scholar 

  14. Gilbert MR, Supko JG, Batchelor T, Lesser G, Fisher JD, Piantadosi S, et al. Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma. Clin Cancer Res. 2003;9(8):2940–9.

    CAS  PubMed  Google Scholar 

  15. Hau P, Fabel K, Baumgart U, Rummele P, Grauer O, Bock A, et al. Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma. Cancer. 2004;100(6):1199–207.

    Article  CAS  PubMed  Google Scholar 

  16. Prados MD, Yung WK, Jaeckle KA, Robins HI, Mehta MP, Fine HA, et al. Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol. 2004;6(1):44–54.

    Article  CAS  PubMed  Google Scholar 

  17. Fruehauf JP, Brem H, Brem S, Sloan A, Barger G, Huang W, et al. In vitro drug response and molecular markers associated with drug resistance in malignant gliomas. Clin Cancer Res. 2006;12(15):4523–32.

    Article  CAS  PubMed  Google Scholar 

  18. Wolff JE, Trilling T, Molenkamp G, Egeler RM, Jurgens H. Chemosensitivity of glioma cells in vitro: a meta analysis. J Cancer Res Clin Oncol. 1999;125(8–9):481–6.

    Article  CAS  PubMed  Google Scholar 

  19. Storm PB, Moriarity JL, Tyler B, Burger PC, Brem H, Weingart J. Polymer delivery of camptothecin against 9L gliosarcoma: release, distribution, and efficacy. J Neurooncol. 2002;56(3):209–17.

    Article  PubMed  Google Scholar 

  20. Storm PB, Renard VM, Moriarity JL, Tyler B, Wilentz RE, Brem H, et al. Systemic BCNU enhances the efficacy of local delivery of a topoisomerase I inhibitor against malignant glioma. Cancer Chemother Pharmacol. 2004;54(4):361–7.

    Article  CAS  PubMed  Google Scholar 

  21. Weingart JD, Thompson RC, Tyler B, Colvin OM, Brem H. Local delivery of the topoisomerase I inhibitor camptothecin sodium prolongs survival in the rat intracranial 9L gliosarcoma model. Int J Cancer. 1995;62(5):605–9.

    Article  CAS  PubMed  Google Scholar 

  22. Lewis AL, Gonzalez MV, Lloyd AW, Hall B, Tang Y, Willis SL, et al. DC bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization. J Vasc Interv Radiol. 2006;17(2 Pt 1):335–42.

    Article  PubMed  Google Scholar 

  23. Gonzalez MV, Tang Y, Phillips GJ, Lloyd AW, Hall B, Stratford PW, et al. Doxorubicin eluting beads-2: methods for evaluating drug elution and in vitro: in vivo correlation. J Mater Sci Mater Med. 2008;19(2):767–75.

    Article  CAS  PubMed  Google Scholar 

  24. Lewis AL, Gonzalez MV, Leppard SW, Brown JE, Stratford PW, Phillips GJ, et al. Doxorubicin eluting beads -1: effects of drug loading on bead characteristics and drug distribution. J Mater Sci Mater Med. 2007;18(9):1691–9.

    Article  CAS  PubMed  Google Scholar 

  25. Taylor RR, Tang Y, Gonzalez MV, Stratford PW, Lewis AL. Irinotecan drug eluting beads for use in chemoembolization: in vitro and in vivo evaluation of drug release properties. Eur J Pharm Sci. 2007;30(1):7–14.

    Article  CAS  PubMed  Google Scholar 

  26. Lewis AL, Taylor RR, Hall B, Gonzalez MV, Willis SL, Stratford PW. Pharmacokinetic and safety study of doxorubicin-eluting beads in a porcine model of hepatic arterial embolization. J Vasc Interv Radiol. 2006;17(8):1335–43.

    Article  PubMed  Google Scholar 

  27. Namur J, Wassef M, Millot J-M, Lewis AL, Manfait M, Laurent A. Doxorubicin eluting beads for liver embolization: pathological findings and correlation with drug distribution in the tissue. J Vasc Interv Radiol. 2010;21:259–67.

    Article  PubMed  Google Scholar 

  28. Druckrey H, Landschutz C, Ivankovic S. Transplacental induction of malignant tumours of the nervous system. II. Ethyl-nitrosurea in 10 genetically defined strains of rats. Z Krebsforsch. 1970;73(4):371–86.

    Article  CAS  PubMed  Google Scholar 

  29. Druckrey H, Schagen B, Ivankovic S. Induction of neurogenic malignancies by one single dose of ethyl-nitrosourea (ENU) given to newborn and juvenile BD IX-strain rats. Z Krebsforsch. 1970;74(2):141–61.

    Article  CAS  PubMed  Google Scholar 

  30. Ozawa T, Wang J, Hu LJ, Bollen AW, Lamborn KR, Deen DF. Growth of human glioblastomas as xenografts in the brains of athymic rats. In Vivo. 2002;16(1):55–60.

    PubMed  Google Scholar 

  31. Yang W, Barth RF, Wu G, Ciesielski MJ, Fenstermaker RA, Moffat BA, et al. Development of a syngeneic rat brain tumor model expressing EGFRvIII and its use for molecular targeting studies with monoclonal antibody L8A4. Clin Cancer Res. 2005;11(1):341–50.

    CAS  PubMed  Google Scholar 

  32. Fournier E, Passirani C, Vonarbourg A, Lemaire L, Colin N, Sagodira S, et al. Therapeutic efficacy study of novel 5-FU-loaded PMM 2.1.2-based microspheres on C6 glioma. Int J Pharm. 2003;268(1–2):31–5.

    Article  CAS  PubMed  Google Scholar 

  33. Fiorentini G, Aliberti C, Turrisi G, Del Conte A, Rossi S, Benea G, et al. Intraarterial hepatic chemoembolization of liver metastases from colorectal cancer adopting irinotecan-eluting beads: results of a phase II clinical study. In Vivo. 2007;21(6):1085–91.

    CAS  PubMed  Google Scholar 

  34. Malagari K, Chatzimichael K, Alexopoulou E, Kelekis A, Hall B, Dourakis S, et al. Transarterial chemoembolization of unresectable hepatocellular carcinoma with drug eluting beads: results of an open-label study of 62 patients. Cardiovasc Intervent Radiol. 2008;31(2):269–80.

    Article  PubMed  Google Scholar 

  35. Menei P, Boisdron-Celle M, Croue A, Guy G, Benoit JP. Effect of stereotactic implantation of biodegradable 5-fluorouracil-loaded microspheres in healthy and C6 glioma-bearing rats. Neurosurgery. 1996;39(1):117–23. discussion 123-4.

    Article  CAS  PubMed  Google Scholar 

  36. Tamargo RJ, Epstein JI, Reinhard CS, Chasin M, Brem H. Brain biocompatibility of a biodegradable, controlled-release polymer in rats. J Biomed Mater Res. 1989;23(2):253–66.

    Article  CAS  PubMed  Google Scholar 

  37. Yamashita Y, Krauze MT, Kawaguchi T, Noble CO, Drummond DC, Park JW, et al. Convection-enhanced delivery of a topoisomerase I inhibitor (nanoliposomal topotecan) and a topoisomerase II inhibitor (pegylated liposomal doxorubicin) in intracranial brain tumor xenografts. Neuro Oncol. 2007;9(1):20–8.

    Article  CAS  PubMed  Google Scholar 

  38. Krauze MT, Noble CO, Kawaguchi T, Drummond D, Kirpotin DB, Yamashita Y, et al. Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts. Neuro Oncol. 2007;9(4):393–403.

    Article  CAS  PubMed  Google Scholar 

  39. Pavillard V, Kherfellah D, Richard S, Robert J, Montaudon D. Effects of the combination of camptothecin and doxorubicin or etoposide on rat glioma cells and camptothecin-resistant variants. Br J Cancer. 2001;85(7):1077–83.

    Article  CAS  PubMed  Google Scholar 

  40. Eyol E, Boleij A, Taylor RR, Lewis AL, Berger MR. Chemoembolisation of rat colorectal liver metastases with drug eluting beads loaded with irinotecan or doxorubicin. Clin Exp Metastasis. 2008;25(3):273–82.

    Article  CAS  PubMed  Google Scholar 

  41. Yang Y, Jiang JS, Du B, Gan ZF, Qian M, Zhang P. Preparation and properties of a novel drug delivery system with both magnetic and biomolecular targeting. J Mater Sci Mater Med. 2009;20(1):301–7.

    Article  CAS  PubMed  Google Scholar 

  42. Fournier E, Passirani C, Montero-Menei C, Colin N, Breton P, Sagodira S, et al. Therapeutic effectiveness of novel 5-fluorouracil-loaded poly(methylidene malonate 2.1.2)-based microspheres on F98 glioma-bearing rats. Cancer. 2003;97(11):2822–9.

    Article  CAS  PubMed  Google Scholar 

  43. Lemaire L, Roullin VG, Franconi F, Venier-Julienne MC, Menei P, Jallet P, et al. Therapeutic efficacy of 5-fluorouracil-loaded microspheres on rat glioma: a magnetic resonance imaging study. NMR Biomed. 2001;14(6):360–6.

    Article  CAS  PubMed  Google Scholar 

  44. Roullin VG, Mege M, Lemaire L, Cueyssac JP, Venier-Julienne MC, Menei P, et al. Influence of 5-fluorouracil-loaded microsphere formulation on efficient rat glioma radiosensitization. Pharm Res. 2004;21(9):1558–63.

    Article  CAS  PubMed  Google Scholar 

  45. Menei P, Capelle L, Guyotat J, Fuentes S, Assaker R, Bataille B, et al. Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of malignant glioma: a randomized phase II trial. Neurosurgery. 2005;56(2):242–8. (discussion 242-8).

    Article  PubMed  Google Scholar 

  46. Menei P, Jadaud E, Faisant N, Boisdron-Celle M, Michalak S, Fournier D, et al. Stereotaxic implantation of 5-fluorouracil-releasing microspheres in malignant glioma. Cancer. 2004;100(2):405–10.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We are grateful to Christiane Bartling for technical assistance. The study was funded by the International Neurobionics Foundation.

Author information

Authors and Affiliations

  1. International Neuroscience Institute GmbH, Rudolf-Pichlmayr-Str. 4, D-30625, Hannover, Germany

    Steffen Baltes, Ina Freund & Thomas Brinker

  2. Biocompatibles UK Ltd, Weydon Lane, Farnham, Surrey, GU9-8QL, UK

    Andrew L. Lewis

  3. University of Veterinary Medicine Hannover, Hannover, Germany

    Ingo Nolte

Authors
  1. Steffen Baltes
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ina Freund
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Andrew L. Lewis
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ingo Nolte
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Thomas Brinker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas Brinker.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Baltes, S., Freund, I., Lewis, A.L. et al. Doxorubicin and irinotecan drug-eluting beads for treatment of glioma: a pilot study in a rat model. J Mater Sci: Mater Med 21, 1393–1402 (2010). https://doi.org/10.1007/s10856-009-3803-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10856-009-3803-4

Keywords

Search

Navigation